These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28302518)

  • 41. A novel SLC12A1 gene mutation associated with hyperparathyroidism, hypercalcemia, nephrogenic diabetes insipidus, and nephrocalcinosis in four patients.
    Wongsaengsak S; Vidmar AP; Addala A; Kamil ES; Sequeira P; Fass B; Pitukcheewanont P
    Bone; 2017 Apr; 97():121-125. PubMed ID: 28095294
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.
    Elgizouli M; Lowe DM; Speckmann C; Schubert D; Hülsdünker J; Eskandarian Z; Dudek A; Schmitt-Graeff A; Wanders J; Jørgensen SF; Fevang B; Salzer U; Nieters A; Burns S; Grimbacher B
    Clin Exp Immunol; 2016 Feb; 183(2):221-9. PubMed ID: 26437962
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunodeficiency due to a novel variant in PIK3CD: a case report.
    Shashaani N; Chavoshzadeh Z; Ghasemi L; Ghotbabadi SH; Shiari S; Sharafian S; Shiari R
    Pediatr Rheumatol Online J; 2023 Jul; 21(1):71. PubMed ID: 37475052
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Resolving the polygenic aetiology of a late onset combined immune deficiency caused by NFKB1 haploinsufficiency and modified by PIK3R1 and TNFRSF13B variants.
    Hargreaves CE; Dhalla F; Patel AM; de Oteyza ACG; Bateman E; Miller J; Anzilotti C; Ayers L; Grimbacher B; Patel SY
    Clin Immunol; 2022 Jan; 234():108910. PubMed ID: 34922003
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase δ Syndrome from the USIDNET Cohort.
    Oh J; Garabedian E; Fuleihan R; Cunningham-Rundles C
    J Allergy Clin Immunol Pract; 2021 Nov; 9(11):4095-4102. PubMed ID: 34352450
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Paradoxical dominant negative activity of an immunodeficiency-associated activating
    Tomlinson PR; Knox R; Perisic O; Su HC; Brierley GV; Williams RL; Semple RK
    bioRxiv; 2023 Dec; ():. PubMed ID: 38077044
    [No Abstract]   [Full Text] [Related]  

  • 47. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K.
    Lucas CL; Zhang Y; Venida A; Wang Y; Hughes J; McElwee J; Butrick M; Matthews H; Price S; Biancalana M; Wang X; Richards M; Pozos T; Barlan I; Ozen A; Rao VK; Su HC; Lenardo MJ
    J Exp Med; 2014 Dec; 211(13):2537-47. PubMed ID: 25488983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Two Monogenetic Disorders, Activated PI3-Kinase-δ Syndrome 2 and Smith-Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling.
    Moreno-Corona N; Chentout L; Poggi L; Thouenon R; Masson C; Parisot M; Mouel LL; Picard C; André I; Cavazzana M; Perrin L; Durandy A; Azarnoush S; Kracker S
    Front Pediatr; 2021; 9():688022. PubMed ID: 34249818
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SHORT syndrome in an adult Brazilian patient.
    Gonçalves ACG; Moretti PN; Cordoba MS; Oliveira RS; Lopes FSC; Oliveira SF; Pic-Taylor A; Castro LC; Mazzeu JF
    Am J Med Genet A; 2022 May; 188(5):1635-1638. PubMed ID: 35080105
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
    Maccari ME; Abolhassani H; Aghamohammadi A; Aiuti A; Aleinikova O; Bangs C; Baris S; Barzaghi F; Baxendale H; Buckland M; Burns SO; Cancrini C; Cant A; Cathébras P; Cavazzana M; Chandra A; Conti F; Coulter T; Devlin LA; Edgar JDM; Faust S; Fischer A; Garcia-Prat M; Hammarström L; Heeg M; Jolles S; Karakoc-Aydiner E; Kindle G; Kiykim A; Kumararatne D; Grimbacher B; Longhurst H; Mahlaoui N; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neven B; Nieters A; Olbrich P; Ozen A; Pachlopnik Schmid J; Picard C; Prader S; Rae W; Reichenbach J; Rusch S; Savic S; Scarselli A; Scheible R; Sediva A; Sharapova SO; Shcherbina A; Slatter M; Soler-Palacin P; Stanislas A; Suarez F; Tucci F; Uhlmann A; van Montfrans J; Warnatz K; Williams AP; Wood P; Kracker S; Condliffe AM; Ehl S
    Front Immunol; 2018; 9():543. PubMed ID: 29599784
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling.
    Walsh CM; Fruman DA
    J Clin Invest; 2014 Sep; 124(9):3688-90. PubMed ID: 25133419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
    Maccari ME; Wolkewitz M; Schwab C; Lorenzini T; Leiding JW; Aladjdi N; Abolhassani H; Abou-Chahla W; Aiuti A; Azarnoush S; Baris S; Barlogis V; Barzaghi F; Baumann U; Bloomfield M; Bohynikova N; Bodet D; Boutboul D; Bucciol G; Buckland MS; Burns SO; Cancrini C; Cathébras P; Cavazzana M; Cheminant M; Chinello M; Ciznar P; Coulter TI; D'Aveni M; Ekwall O; Eric Z; Eren E; Fasth A; Frange P; Fournier B; Garcia-Prat M; Gardembas M; Geier C; Ghosh S; Goda V; Hammarström L; Hauck F; Heeg M; Heropolitanska-Pliszka E; Hilfanova A; Jolles S; Karakoc-Aydiner E; Kindle GR; Kiykim A; Klemann C; Koletsi P; Koltan S; Kondratenko I; Körholz J; Krüger R; Jeziorski E; Levy R; Le Guenno G; Lefevre G; Lougaris V; Marzollo A; Mahlaoui N; Malphettes M; Meinhardt A; Merlin E; Meyts I; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neubert J; Neven B; Nieters A; Nove-Josserand R; Oksenhendler E; Ozen A; Olbrich P; Perlat A; Pac M; Schmid JP; Pacillo L; Parra-Martinez A; Paschenko O; Pellier I; Sefer AP; Plebani A; Plantaz D; Prader S; Raffray L; Ritterbusch H; Riviere JG; Rivalta B; Rusch S; Sakovich I; Savic S; Scheible R; Schleinitz N; Schuetz C; Schulz A; Sediva A; Semeraro M; Sharapova SO; Shcherbina A; Slatter MA; Sogkas G; Soler-Palacin P; Speckmann C; Stephan JL; Suarez F; Tommasini A; Trück J; Uhlmann A; van Aerde KJ; van Montfrans J; von Bernuth H; Warnatz K; Williams T; Worth AJJ; Ip W; Picard C; Catherinot E; Nademi Z; Grimbacher B; Forbes Satter LR; Kracker S; Chandra A; Condliffe AM; Ehl S;
    J Allergy Clin Immunol; 2023 Oct; 152(4):984-996.e10. PubMed ID: 37390899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
    Jamee M; Moniri S; Zaki-Dizaji M; Olbrich P; Yazdani R; Jadidi-Niaragh F; Aghamahdi F; Abolhassani H; Condliffe AM; Aghamohammadi A; Azizi G
    Clin Rev Allergy Immunol; 2020 Dec; 59(3):323-333. PubMed ID: 31111319
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Two hits in one: whole genome sequencing unveils LIG4 syndrome and urofacial syndrome in a case report of a child with complex phenotype.
    Fadda A; Butt F; Tomei S; Deola S; Lo B; Robay A; Al-Shakaki A; Al-Hajri N; Crystal R; Kambouris M; Wang E; Marincola FM; Fakhro KA; Cugno C
    BMC Med Genet; 2016 Nov; 17(1):84. PubMed ID: 27855655
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PI3K pathway defects leading to immunodeficiency and immune dysregulation.
    Nunes-Santos CJ; Uzel G; Rosenzweig SD
    J Allergy Clin Immunol; 2019 May; 143(5):1676-1687. PubMed ID: 31060715
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Generation, establishment and characterization of a pluripotent stem cell line (CVTTHi001-A) from primary fibroblasts isolated from a patient with activated PI3 kinase delta syndrome (APDS2).
    Inglés-Ferrándiz M; Martin-Inaraja M; Herrera L; Villaverde M; Santos S; Vesga MA; Garreta E; Martín-Ruiz I; Aransay AM; Anguita J; Barreña B; Allende LM; Gonzalez-Granado LI; Eguizabal C
    Stem Cell Res; 2020 Dec; 49():102082. PubMed ID: 33221676
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical and immunological characteristics of a case with activated phosphoinositide 3-kinase δ syndrome 2].
    Yang QY; Jia YJ; Wang YP; Zeng T; Zhao XD; Zhou LN
    Zhonghua Er Ke Za Zhi; 2020 May; 58(5):413-417. PubMed ID: 32392959
    [No Abstract]   [Full Text] [Related]  

  • 58. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.
    Luo Y; Xia Y; Wang W; Li Z; Jin Y; Gong Y; He T; Li Q; Li C; Yang J
    Clin Immunol; 2018 Dec; 197():60-67. PubMed ID: 30138677
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling.
    Chudasama KK; Winnay J; Johansson S; Claudi T; König R; Haldorsen I; Johansson B; Woo JR; Aarskog D; Sagen JV; Kahn CR; Molven A; Njølstad PR
    Am J Hum Genet; 2013 Jul; 93(1):150-7. PubMed ID: 23810379
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term follow-up of an activated PI3K-δ syndrome 2 in patient presenting with an agammaglobulinemia phenotype.
    Nguyen Y; Rosain J; Aguilar C; Picard C; Malphettes M
    Ann Allergy Asthma Immunol; 2018 Dec; 121(6):739-740.e1. PubMed ID: 30081089
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.